Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9393) 9393
Publication (605) 605
Book Chapter (153) 153
Dissertation (121) 121
Book Review (101) 101
Conference Proceeding (92) 92
Book / eBook (9) 9
Web Resource (6) 6
Data Set (5) 5
Magazine Article (3) 3
Government Document (2) 2
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4580) 4580
drug interactions (3418) 3418
pharmacology & pharmacy (3414) 3414
index medicus (2900) 2900
drug-drug interactions (2886) 2886
animals (2659) 2659
male (2285) 2285
drug-drug interaction (2188) 2188
pharmacokinetics (1558) 1558
female (1492) 1492
rats (1090) 1090
receptors, drug - drug effects (1049) 1049
adult (974) 974
middle aged (858) 858
metabolism (835) 835
in-vitro (715) 715
aged (643) 643
pharmacology (596) 596
dose-response relationship, drug (590) 590
drug–drug interaction (586) 586
analysis (571) 571
inhibition (559) 559
mice (546) 546
drugs (513) 513
toxicology (496) 496
drug–drug interactions (495) 495
kinetics (482) 482
p-glycoprotein (474) 474
cytochrome p450 (430) 430
in vitro techniques (424) 424
biochemistry & molecular biology (421) 421
drug interaction (410) 410
cytochrome p-450 enzyme system - metabolism (407) 407
cytochrome p-450 (394) 394
young adult (375) 375
area under curve (372) 372
drug therapy, combination (359) 359
models, biological (359) 359
pharmacology/toxicology (344) 344
research (341) 341
chemistry, multidisciplinary (338) 338
enzymes (318) 318
receptors, drug - metabolism (313) 313
drug therapy (311) 311
liver (306) 306
human liver-microsomes (300) 300
prediction (294) 294
rats, sprague-dawley (294) 294
adolescent (291) 291
administration, oral (279) 279
time factors (270) 270
pharmacy (269) 269
metabolites (266) 266
therapy (265) 265
cytochrome p-450 cyp3a - metabolism (262) 262
polypharmacy (261) 261
liver - metabolism (257) 257
cells, cultured (254) 254
chemistry, medicinal (254) 254
pharmaceutical preparations - metabolism (251) 251
cancer (247) 247
cross-over studies (247) 247
cyp3a4 (245) 245
physiological aspects (245) 245
microsomes, liver - metabolism (242) 242
complications and side effects (241) 241
pharmacodynamics (239) 239
drug design (230) 230
medicine & public health (230) 230
protein binding (230) 230
aged, 80 and over (229) 229
oncology (229) 229
safety (224) 224
biomedicine (221) 221
enzyme inhibitors - pharmacology (216) 216
expression (216) 216
article (215) 215
risk factors (215) 215
microsomes, liver - drug effects (213) 213
internal medicine (209) 209
microsomes, liver - enzymology (206) 206
drug metabolism (203) 203
induction (201) 201
binding sites (199) 199
drug synergism (196) 196
warfarin (192) 192
care and treatment (188) 188
risk (187) 187
structure-activity relationship (187) 187
cell line (186) 186
rats, wistar (186) 186
dosage and administration (184) 184
absorption (177) 177
healthy-volunteers (176) 176
hiv (176) 176
health aspects (174) 174
inhibitors (173) 173
prevalence (172) 172
ketoconazole (171) 171
liver - drug effects (171) 171
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6330) 6330
Japanese (1793) 1793
Chinese (1410) 1410
German (63) 63
French (41) 41
Russian (27) 27
Spanish (23) 23
Slovenian (9) 9
Czech (7) 7
Korean (6) 6
Portuguese (6) 6
Polish (5) 5
Hungarian (2) 2
Italian (2) 2
Bulgarian (1) 1
Norwegian (1) 1
Slovak (1) 1
Thai (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction
by Kenny, Jane R and Mukadam, Sophie and Zhang, Chenghong and Tay, Suzanne and Collins, Carol and Galetin, Aleksandra and Khojasteh, S Cyrus
Pharmaceutical Research, ISSN 0724-8741, 7/2012, Volume 29, Issue 7, pp. 1960 - 1976
To evaluate 26 marketed oncology drugs for time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes. Evaluate TDI-positive drugs for potential to... 
Biomedical Engineering | Biochemistry, general | Biomedicine | kinase inhibitors | time-dependent CYP inhibition | Pharmacy | prediction | Medical Law | reactive metabolites | Pharmacology/Toxicology | drug-drug interaction | 3A4 | BIOACTIVATION | MODEL | CHEMISTRY, MULTIDISCIPLINARY | MECHANISM-BASED INACTIVATION | PHARMACOKINETICS | ENZYMES | PHARMACOLOGY & PHARMACY | CYP3A4 INHIBITION | MIDAZOLAM | ERLOTINIB | Cytochrome P-450 Enzyme Inhibitors | Area Under Curve | Humans | Cytochrome P-450 Enzyme System - metabolism | Antineoplastic Agents - chemistry | Blood Proteins - metabolism | Neoplasms - drug therapy | Antineoplastic Agents - metabolism | Protein Kinase Inhibitors - chemistry | Drug Interactions | Microsomes, Liver - drug effects | Models, Biological | Antineoplastic Agents - pharmacology | Microsomes, Liver - enzymology | Protein Kinase Inhibitors - pharmacology | Protein Kinase Inhibitors - metabolism | Drugs | Physiological aspects | Enzymes | Metabolites | Drug interactions | Cytochrome P-450 | Drug therapy | Oncology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs
by Kakuda, Thomas N and Schöller-Gyüre, Monika and Hoetelmans, Richard M. W
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study
by Muhič, Neža and Mrhar, Ales and Brvar, Miran
European Journal of Clinical Pharmacology, ISSN 0031-6970, 07/2017, Volume 73, Issue 7, pp. 875 - 882
Purpose Drug-drug interaction (DDI) screening systems report potential DDIs. This study aimed to find the prevalence of probable DDI-related adverse drug... 
Drug–drug interaction screening systems | Adverse drug reactions | Potential drug–drug interactions | Actual drug–drug interactions | Drug-drug interaction screening systems | Potential drug-drug interactions | EMERGENCY-DEPARTMENT | INTENSIVE-CARE-UNIT | INTERACTION SOFTWARE | PHARMACOLOGY & PHARMACY | Actual drug-drug interactions | ALERTS | SEVERITY | Drug Interactions | Drug-Related Side Effects and Adverse Reactions - prevention & control | Prospective Studies | Humans | Hospitalization - statistics & numerical data | Female | Male | Aged | Drug Information Services | Tertiary Care Centers - statistics & numerical data | Medicine, Experimental | Medical research | Comparative analysis | Drug interactions | Drugs | Sensitivity analysis | Toxicity | Digitalis | Systems analysis | Medical screening | Patients | Bleeding | Hypotension | Screening | Side effects | Sensitivity | Hyperkalemia | Drug interaction | Internet | Health risk assessment | Statins | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: A systematic review on CYP2C9, CYP2C19 and CYP2D6
by Bahar, Muh Akbar and Setiawan, Didik and Hak, Eelko and Wilffert, Bob
Pharmacogenomics, ISSN 1462-2416, 05/2017, Volume 18, Issue 7, pp. 701 - 739
Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor... 
drug-drug interaction (DDI) | CYP2C9 | drug-metabolizing enzyme | CYP2C19 | CYP2D6 | drug-drug-gene interaction (DDGI) | LOW-DOSE QUINIDINE | POOR METABOLIZERS | LANSOPRAZOLE PHARMACOKINETICS | GENETICALLY-DETERMINED INTERACTION | ENANTIOSELECTIVE DISPOSITION | PLASMA-CONCENTRATIONS | PROTON PUMP INHIBITOR | GENOTYPE STATUS | LIVER-TRANSPLANT PATIENTS | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | Cytochrome P-450 CYP2D6 - genetics | Pharmacogenetics - methods | Pharmacogenetics - trends | Animals | Drug Interactions - genetics | Humans | Cytochrome P-450 CYP2C19 - genetics | Cytochrome P-450 CYP2D6 - metabolism | Cytochrome P-450 CYP2C19 - metabolism | Inactivation, Metabolic - genetics | Cytochrome P-450 CYP2C9 - metabolism | Cytochrome P-450 CYP2C9 - genetics
Journal Article
Details down arrow
5. Full Text Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
by Prueksaritanont, Thomayant and Chu, Xiaoyan and Gibson, Christopher and Cui, Donghui and Yee, Ka Lai and Ballard, Jeanine and Cabalu, Tamara and Hochman, Jerome
The AAPS Journal, ISSN 1550-7416, 7/2013, Volume 15, Issue 3, pp. 629 - 645
Recently, the US Food and Drug Administration and European Medicines Agency have issued new guidance for industry on drug interaction studies, which outline... 
Biochemistry, general | Biotechnology | Biomedicine | Pharmacy | drug–drug interaction studies | regulatory guidance | Pharmacology/Toxicology | industry perspective | drug-drug interaction studies | POLYMORPHISM MARKEDLY AFFECTS | ADULT MALE-VOLUNTEERS | HEPATIC-UPTAKE | TRANSPORTING POLYPEPTIDE 1B1 | P-GLYCOPROTEIN | CYCLOSPORINE-A | HUMAN HEPATOCYTES | PLASMA-CONCENTRATIONS | IN-VIVO | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | Pharmaceutical Preparations - metabolism | Animals | Pharmaceutical Preparations - standards | European Union | Practice Guidelines as Topic - standards | United States | Humans | United States Food and Drug Administration - standards | Drug Interactions - physiology | United States Food and Drug Administration - legislation & jurisprudence | Physiological aspects | Enzymes | Invisibility | Analysis | Drug interactions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The multimorbidity interaction severity index (MISI) A proof of concept study
by Gassmann, Dimitri and Cheetham, Marcus and Siebenhuener, Klarissa and Holzer, Barbara M and Meindl-Fridez, Claudine and Hildenbrand, Florian F and Virgini, Vanessa and Martin, Mike and Battegay, Edouard
Medicine (United States), ISSN 0025-7974, 2017, Volume 96, Issue 8, p. e6144
Therapeutic decision-making for patients with multimorbidity (MM) is challenging. Clinical practice guidelines inadequately address harmful interactions and... 
Severity index | MISI | Computerized decision support | Drug-drug interactions | Drug-disease interactions | Therapeutic conflict | Multimorbidity | RANDOMIZED CONTROLLED-TRIALS | QUALITY | multimorbidity | severity index | drug-disease interactions | PREVALENCE | COMORBIDITY | therapeutic conflict | CLINICAL-PRACTICE GUIDELINES | CO-MORBIDITY | MEDICINE, GENERAL & INTERNAL | drug-drug interactions | PRIMARY-CARE | computerized decision support | DISEASE | HEALTH-CARE | MULTIPLE CHRONIC CONDITIONS | Severity of Illness Index | Comorbidity | Physicians | Humans | Internal Medicine - methods | Decision Support Systems, Clinical | Female | Male | Decision Making, Computer-Assisted | Decision-making | Usage | Analysis | Practice guidelines (Medicine) | Management | Patient compliance | Morbidity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Potential Pharmacokinetic Drug-Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
by Zhang, YP and Li, SP and Wang, YX and Deng, G and Cao, N and Wu, C and Ding, WZ and Wang, YW and Cheng, XM and Wang, CH
MOLECULES, ISSN 1420-3049, 04/2019, Volume 24, Issue 7, p. 1430
Harmine (HAR) is a beta-carboline alkaloid widely distributed in nature. It exhibits psychopharmacological effects of improving learning and memory. However,... 
SYSTEM | DEMENTIA | RAT | memantine | liquid chromatography-mass spectrometry | ALZHEIMERS-DISEASE | HARMALINE | BIOCHEMISTRY & MOLECULAR BIOLOGY | harmine | MODEL | CHEMISTRY, MULTIDISCIPLINARY | BETA-CARBOLINE ALKALOIDS | MEMORY | pharmacokinetics | SPECIES-DIFFERENCES | MPTP | drug-drug interaction | Alzheimer's disease | Alzheimer’s disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Drug-drug interaction through molecular structure similarity analysis
by Vilar, Santiago and Harpaz, Rave and Uriarte, Eugenio and Santana, Lourdes and Rabadan, Raul and Friedman, Carol
Journal of the American Medical Informatics Association, ISSN 1067-5027, 11/2012, Volume 19, Issue 6, pp. 1066 - 1074
Background Drug-drug interactions (DDIs) are responsible for many serious adverse events; their detection is crucial for patient safety but is very... 
ADMISSIONS | HOSPITALIZED-PATIENTS | EVENTS | PERSPECTIVE | MEDICAL INFORMATICS | COMPUTER SCIENCE, INFORMATION SYSTEMS | RECEPTOR | RHABDOMYOLYSIS | DISCOVERY | COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | INTERNAL-MEDICINE | HEALTH CARE SCIENCES & SERVICES | INFORMATION SCIENCE & LIBRARY SCIENCE | CHEMISTRY | LIGAND | Databases, Pharmaceutical | Drug Interactions | United States | Drug-Related Side Effects and Adverse Reactions | Humans | Sensitivity and Specificity | Models, Molecular | Pharmaceutical Preparations - classification | ROC Curve | Molecular Structure | Pharmacovigilance | Forecasting | Research and Applications | statistical analysis of large datasets | QSAR | molecular modeling | drug design | and text and data mining methods | discovery | adverse drug event | automated learning | Drug-drug interaction | structure similarity | molecular fingerprints
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Time‐dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine–warfarin interaction
by Fang, Zhong‐Ze and Zhang, Yan‐Yan and Ge, Guang‐Bo and Huo, Hong and Liang, Si‐Cheng and Yang, Ling
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2010, Volume 69, Issue 2, pp. 193 - 199
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Clinical cases reported to the Swedish adverse drug interactions register (SWEDIS) indicated that drug–drug... 
noscapine | time‐dependent inhibition | drug–drug interaction | cytochrome P450 (CYP) | warfarin | Warfarin | Noscapine | Time-dependent inhibition | Drug-drug interaction | Cytochrome P450 (CYP) | CLEARANCE | APOPTOSIS | time-dependent inhibition | PREDICTION | AGENT | METABOLISM | PHARMACOKINETICS | CYTOCHROME-P450 ENZYMES | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | drug-drug interaction | BINDING | DRUG-DRUG INTERACTIONS | Cytochrome P-450 CYP2C9 | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Models, Chemical | Anticoagulants - metabolism | Cytochrome P-450 CYP3A | Tissue Culture Techniques | Humans | Middle Aged | Warfarin - metabolism | Male | Dose-Response Relationship, Drug | Cytochrome P-450 CYP3A Inhibitors | Drug Interactions | Time Factors | Microsomes, Liver - drug effects | Models, Biological | Adult | Antitussive Agents - metabolism | Noscapine - metabolism | Enzyme inhibitors | Drug interactions | Cytochrome P-450 | Short Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Transporter-mediated drug-drug interactions
by Müller, Fabian and Fromm, Martin F
Pharmacogenomics, ISSN 1462-2416, 07/2011, Volume 12, Issue 7, pp. 1017 - 1037
Drug-drug interactions are a serious clinical issue. An important mechanism underlying drug-drug interactions is induction or inhibition of drug transporters... 
probenecid | P-gp | aliskiren | fexofenadine | digoxin | OAT1 | drug transporter | OATP1B1 | OAT3 | OCT2 | MATE1 | cimetidine | drug-drug interaction | rosuvastatin | TOXIN EXTRUSION 1 | INTESTINAL P-GLYCOPROTEIN | PHARMACOLOGY & PHARMACY | ST-JOHNS-WORT | DIGOXIN-QUINIDINE INTERACTION | CANCER RESISTANCE PROTEIN | CISPLATIN-INDUCED NEPHROTOXICITY | ORGANIC ANION TRANSPORTERS | DIRECT RENIN INHIBITOR | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | COA-REDUCTASE INHIBITORS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Organic Cation Transport Proteins - metabolism | Humans | Liver - metabolism | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Neoplasm Proteins - metabolism | Organic Anion Transporters - metabolism | Kidney - metabolism | Organic Anion Transporters - genetics | Drug Interactions | ATP-Binding Cassette Transporters - metabolism | Xenobiotics - metabolism | Intestine, Small - metabolism | Organic Cation Transport Proteins - genetics | Drugs | organic anion transporting polypeptide | Liver | Breast cancer | Small intestine | Kidney | Protein turnover | Anions | organic cation transporter | Drug metabolism | Toxins | Pharmacokinetics | Xenobiotics | Probes
Journal Article
Details down arrow
11. Full Text Methadone—metabolism, pharmacokinetics and interactions
by Ferrari, Anna and Coccia, Ciro Pio Rosario and Bertolini, Alfio and Sternieri, Emilio
Pharmacological Research, ISSN 1043-6618, 2004, Volume 50, Issue 6, pp. 551 - 559
The pharmacokinetics of methadone varies greatly from person to person; so, after the administration of the same dose, considerably different concentrations... 
Methadone | CYP3A4 | CYP2D6 | Pharmacokinetic | Drug–drug interactions | Drug-drug interactions | MAINTENANCE TREATMENT | OPIATE WITHDRAWAL | RECEIVING METHADONE | PROTEASE INHIBITORS | STEADY-STATE CONCENTRATIONS | CLINICAL-RELEVANCE | drug-drug interactions | INJECTION-DRUG USERS | INHIBITOR LOPINAVIR-RITONAVIR | PLASMA-LEVELS | HIV-POSITIVE PATIENTS | PHARMACOLOGY & PHARMACY | pharmacokinetic | methadone | Animals | Methadone - blood | Cytochrome P-450 CYP3A | Humans | Drug Interactions - physiology | Cytochrome P-450 Enzyme System - metabolism | Methadone - metabolism | Methadone - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Interaction between warfarin and cannabis
by Damkier, Per and Lassen, Dorte and Christensen, Mette Marie Hougaard and Madsen, Kenneth Grønkjær and Hellfritzsch, Maja and Pottegård, Anton
Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, 01/2019, Volume 124, Issue 1, pp. 28 - 31
Delta‐9‐tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, may inhibit the cytochrome P450 enzyme CYP2C9. Consequently, cannabis use... 
cannabis | case report | MiniReview | drug‐drug interaction | warfarin | drug-drug interaction | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Marijuana Smoking - adverse effects | Stroke - prevention & control | Humans | Anticoagulants - therapeutic use | Male | Substance-Related Disorders - complications | Warfarin - pharmacology | Warfarin - therapeutic use | International Normalized Ratio | Stroke - blood | Cannabis - chemistry | Stroke - etiology | Cytochrome P-450 CYP2C9 Inhibitors - pharmacology | Drug Interactions | Heart Valve Prosthesis Implantation - adverse effects | Anticoagulants - pharmacology | Adult | Dronabinol - pharmacology | Cytochrome P-450 CYP2C9 - metabolism | Endocarditis - surgery | Cytochrome | Drug abuse | Enzymes | Warfarin | Epilepsy | Cytochrome P450 | Drug interactions | Case reports | Metabolism | Patients | Heart valves | Substrates | Bleeding | Literature reviews | Case studies | Cannabis | Recreational use | Cannabinoids | Marijuana | Drug interaction | Tetrahydrocannabinol | Cytochromes P450
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Recent trends in preclinical drug–drug interaction studies of flavonoids — Review of case studies, issues and perspectives
by Srinivas, Nuggehally R
Phytotherapy Research, ISSN 0951-418X, 11/2015, Volume 29, Issue 11, pp. 1679 - 1691
Because of health benefits that are manifested across various disease areas, the consumption of herbal products and/or health supplements containing different... 
Drug drug interaction | Flavonoids | Bioavailability | Metabolism | Pharmacokinetics | Absoprtion | CHEMISTRY, MEDICINAL | CYCLOSPORINE BIOAVAILABILITY | CYTOCHROME-P450 3A4 | MARKED DECREASE | RATS POSSIBLE ROLE | IN-VITRO | ORAL BIOAVAILABILITY | PHARMACOLOGY & PHARMACY | PHASE-I | P-GLYCOPROTEIN INHIBITION | KINASE INHIBITOR FLAVOPIRIDOL | ACTIVE METABOLITE | Drug Interactions | Humans | Quercetin | Antineoplastic Agents | Biological Availability | Tamoxifen | Doxorubicin | Felodipine | Case studies | Drug interactions | Isoflavones
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights